Welcome to our dedicated page for Vor Biopharma SEC filings (Ticker: VOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Deciphering a clinical-stage biotech filing can feel like running a lab experiment without the protocol. Vor Biopharma鈥檚 10-K spans pages of gene-editing details, cash-burn tables, and licensing clauses that leave many investors asking, 鈥淲here do I start?鈥�
Stock Titan answers with AI-powered clarity. Our platform scans every new document the second it lands on EDGAR鈥攚hether it鈥檚 an 8-K material events notice on fresh trial data or a Form 4 insider transaction that hints at executive sentiment. Type a natural question like 鈥渦nderstanding Vor Biopharma SEC documents with AI鈥� or 鈥渉ow to read the Vor Biopharma annual report 10-K simplified,鈥� and get plain-English summaries, key financial metrics, and direct page links within seconds.
Here鈥檚 what you can explore in one dashboard:
- Vor Biopharma quarterly earnings report 10-Q filing鈥擜I highlights shifts in R&D spend and runway.
- Vor Biopharma insider trading Form 4 transactions鈥攔eal-time alerts on buys, sells, and option grants.
- Vor Biopharma proxy statement executive compensation鈥攂reakdowns of equity awards tied to clinical milestones.
- Vor Biopharma 8-K material events explained鈥攕peed-read summaries of trial pauses, FDA designations, or financing rounds.
Need deeper context? Our AI cross-references historical filings for trendlines, delivering a concise Vor Biopharma earnings report filing analysis with year-over-year R&D and dilution impacts. Investors monitoring 鈥淰or Biopharma Form 4 insider transactions real-time鈥� or evaluating risk factors no longer have to sift through biotech jargon鈥擲tock Titan surfaces what matters so you can focus on decisions, not documents.
QUALCOMM (QCOM) FY25 Q3 (13 weeks ended 6/29/25)
- Revenue: $10.37 B, +10% YoY; gross margin steady at 56%.
- Net income: $2.67 B, +25% YoY; diluted EPS $2.43, +29% YoY.
- Segment mix: QCT $8.99 B (+11%); handset $6.33 B, IoT $1.68 B (+24%), automotive $0.98 B (+21%). QCT EBT margin rose to 30% (27%). QTL licensing $1.32 B (+4%) with 71% margin.
- Nine-month cash flow: operating cash $10.0 B (+5%); capex $0.8 B; buybacks $6.35 B (41 M shares), dividends $2.85 B; $9.7 B repurchase authority remains.
- Balance sheet: cash & securities $12.3 B incl. $2.3 B restricted for the $2.4 B Alphawave acquisition; inventories flat at $6.34 B; long-term debt $14.8 B (issued $1.5 B new notes, repaid $1.4 B).
- Tax: effective rate 10% Q3, 11% YTD; upcoming OBBB law could raise GAAP tax expense from FY26 but cut cash taxes.
- Customer concentration: top three OEMs contributed 52% of Q3 revenue (21%,18%,13%).
- Litigation / regulatory: ongoing Arm and ParkerVision cases; no loss accruals recorded.
Overall, strong top-line growth, margin resilience and robust cash generation were partly offset by heavier leverage, customer concentration and pending regulatory/tax headwinds.
Vor Biopharma鈥檚 preliminary proxy outlines three critical proposals that require shareholder approval at a 2025 special meeting held virtually.
- Issuance Proposal: Ratifies up to 1.02 B common shares underlying low-priced ($0.0001) warrants sold in June 2025 (700 M pre-funded; 320 M to RemeGen). Gross exercise proceeds would be only $102 K, but the private placement already generated $175 M cash for operations; exercise is blocked until shareholders approve under Nasdaq Rule 5635(d).
- Reverse Stock Split: Authorises the board to combine shares within a 1-for-5 to 1-for-30 range any time within a year. Goals: preserve Nasdaq listing after repeated <$1 price notices, create sufficient authorised shares for warrant exercises, and enhance marketability.
- Equity Plan Amendment: Adds 25 M shares to the 2021 Equity Incentive Plan, extends the evergreen through 2035 at 4% (down from 5%) of outstanding shares annually, and lifts the ISO limit to 138.0 M shares.
Support agreements covering an undisclosed but 鈥渁pproximate鈥� majority of voting power commit those holders to vote FOR Proposals 1 & 2. Failure to pass Proposal 1 forces costly repeat meetings; failure to pass Proposal 2 risks Nasdaq delisting and limits share availability. All proposals require a simple majority of votes cast; broker non-votes are not counted.
Vor Biopharma Inc. (VOR) 鈥� Form 144 insider sale filing
President & CEO Robert Ang has filed a Form 144 indicating his intent to sell 214,135 common shares through Morgan Stanley Smith Barney on or after 15 Jul 2025. The shares have an aggregate market value of $520,586, based on the filing鈥檚 reference price, and represent roughly 0.17 % of the company鈥檚 124.96 million shares outstanding.
The filing also discloses that Ang has already disposed of approximately 722,916 shares in the past three months, generating gross proceeds of about $1.49 million. Combined, recent and proposed sales total nearly 0.75 % of outstanding shares.
Form 144 serves as a notice of proposed sales of restricted or control securities and does not guarantee execution. Nevertheless, multiple sales in a short period signal meaningful insider monetisation activity that investors often monitor as a sentiment indicator.
- Shares to be sold: 214,135
- Broker: Morgan Stanley Smith Barney, NY
- Past 3-month sales: 722,916 shares
- Total shares outstanding: 124,959,520
FAQ
What is the current stock price of Vor Biopharma (VOR)?
What is the market cap of Vor Biopharma (VOR)?
What is the primary focus of Vor Biopharma Inc?
How does Vor Biopharma\'s technology work?
What types of therapies are integrated into their platform?
In which market segment does Vor Biopharma operate?
What are the key differentiators of Vor Biopharma?
How does Vor Biopharma manage the risks associated with advanced therapies?
What role does intellectual property play in Vor Biopharma\'s strategy?
How does Vor Biopharma ensure operational excellence?
